Having already secured the thumbs-up in the US for two of the five product approvals it expects in 2025, GSK’s attention is turning to the other three, with Nucala next in line as a potential treatment for chronic obstructive pulmonary disease (COPD).
Key Takeaways
- The FDA will decide on whether to approve GSK's asthma blockbuster for COPD by 7 May.
Following the recent approvals from the US Food and Drug Administration for the 5-in-1 meningococcal vaccine
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?